Sygnature Discovery is a worldleading integrated drug discovery contract research organisation based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield and Glasgow (UK), as well as Montreal and Quebec City (Canada).

Its team of over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech, and NFP organisations. Since 2004, Sygnature Discovery has delivered over 40 novel preclinical and 25 clinical compounds, with its scientists named on over 170 patents.

Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.

For further information, visit www.sygnaturediscovery.com